 AIM ImmunoTech Inc NYSE:AIM announced that its dsRNA product candidate Ampligen rintatolimod has been granted Orphan Drug Designation by the US Food and Drug Administration FDA for the treatment of Ebola virus disease. The company said it was developing Ampligen for globally important cancers, viral diseases, and disorders of the immune system. 